Phaseline

Targets › ASPA

ASPA (Aspartoacylase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Oct 2032.

Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. (UniProt, P45381)

Open in Phaseline: the race on ASPA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Aspa TherapeuticsAAV9 BBP-812
Adeno-associated virus serotype 9 (AAV9) delivering aspartoacylase (ASPA) gene
ASPAPhase 1Canavan DiseaseOct 2032

Conditions

Canavan Disease (1)

Modalities

other (1)

Companies

Aspa Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.